Natera Receives Favorable Medicare Reimbursement Pricing for Prospera
N
atera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at USD 2,840.75.
Natera has achieved every commercial milestone on time and we are looking forward to a successful launch, said Steve Chapman, Natera's CEO.
The Prospera test has been validated to detect both clinical and subclinical rejection, including T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR).1 Its use may help physicians identify rejection events, avoid unnecessary biopsies, and optimize patient care.
✔️ Natera Receives Favorable Medicare Reimbursement Pricing for Prospera
💕 Found this article helpful? Spread the word and support us!